Tatva Chintan Pharma Chem Ltd's Q3FY25 Quarter Results
- 29 Jan 2025
Result Summary
- Tatva Chintan Pharma Chem Ltd reported a 2.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 0.6%.
- Its expenses for the quarter were up by 1.5% QoQ and 7.5% YoY.
- The net profit decreased 121.2% QoQ and decreased 96.0% YoY.
- The earnings per share (EPS) of Tatva Chintan Pharma Chem Ltd stood at 0.1 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 85.94 | 83.87 | 85.42 | 2.5% | 0.6% |
Total Expenses | 86.18 | 84.88 | 80.17 | 1.5% | 7.5% |
Profit Before Tax | -0.24 | -1.02 | 5.24 | -76.5% | -104.6% |
Tax | -0.37 | -0.36 | 1.79 | 2.8% | -120.7% |
Profit After Tax | 0.14 | -0.66 | 3.46 | -121.2% | -96.0% |
Earnings Per Share | 0.10 | -0.30 | 1.50 | -133.3% | -93.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Tatva Chintan Pharma Chem Ltd is a prominent entity in the chemical industry, focusing primarily on manufacturing specialty chemicals. These products serve diverse applications, including pharmaceuticals, agrochemicals, personal care, and paints and coatings. The company is reputed for its innovative processes and commitment to sustainability. Noteworthy developments around the company include its continuous effort to expand its product portfolio and enhance its production capabilities to cater to increasing global demand. However, any recent specific major developments or strategic partnerships are not available in the provided data.
Revenue
In the third quarter of fiscal year 2025, Tatva Chintan Pharma Chem Ltd reported a total income of ₹85.94 crores. This reflects a quarter-over-quarter (QoQ) increase of 2.5% from ₹83.87 crores in Q2FY25, and a slight year-over-year (YoY) growth of 0.6% from ₹85.42 crores in Q3FY24. The data indicates a steady revenue performance, maintaining growth over both the previous quarter and the same quarter last year. This performance highlights the company's ability to sustain its income levels amidst varying market conditions.
Profitability
Profitability metrics for Tatva Chintan Pharma Chem Ltd in Q3FY25 reveal a complex picture. The company recorded a profit before tax (PBT) of -₹0.24 crores, which shows a significant improvement from the preceding quarter's PBT of -₹1.02 crores, marking a -76.5% QoQ change. However, on a YoY basis, there is a steep decline from a PBT of ₹5.24 crores in Q3FY24, showing a -104.6% change. The tax expense for Q3FY25 was -₹0.37 crores, slightly up from -₹0.36 crores in Q2FY25, and a substantial decrease from ₹1.79 crores in Q3FY24. Consequently, the profit after tax (PAT) for Q3FY25 stood at ₹0.14 crores, an improvement from the previous quarter's -₹0.66 crores, but significantly lower than ₹3.46 crores in the same quarter of the previous year. Earnings per share (EPS) followed a similar trend, recording at ₹0.10 in Q3FY25, compared to -₹0.30 in Q2FY25 and ₹1.50 in Q3FY24.
Operating Metrics
Operating expenses for Tatva Chintan Pharma Chem Ltd have shown a notable increase. Total expenses in Q3FY25 amounted to ₹86.18 crores, which is a 1.5% rise from ₹84.88 crores in Q2FY25, and a 7.5% increase from ₹80.17 crores in Q3FY24. This increase in expenses impacts the bottom line, reflecting in the profitability metrics. The company's ability to manage its expenses in relation to its income is crucial for financial health. The data provided does not include specific financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio, which are often used to evaluate operational efficiency and financial stability.
